Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
Patients suffering from schizophrenia have a high risk to become obese and develop diabetes.
Risk of obesity is particularly high with some newer schizophrenia drugs, such as clozapine
or olanzapine. These drugs are called atypical drugs and exert their action in part by
occupying receptors for serotonin, particularly the 5HT2A receptor subtype. This receptor may
also interfere with glucose metabolism and insulin action. The purpose of this study is to
compare an atypical antipsychotic drugs, olanzapine, which acts by occupying the 5HT2A
receptor, to another antipsychotic drug, amisulpride, which mainly acts through the dopamine
pathway. Healthy volunteers are recruited and asked to take a single dose of each drug and of
placebo on separate days. Then, a combined glucose clamp study will be performed in order to
test the effects of these drugs on insulin sensitivity and insulin secretion.